Do Wall Street Analysts Like Incyte Corporation Stock?

Incyte Corp_ logo and bar chart-by Piotr Swat via Shutterstock

Aanchal Sugandh

Thu, February 12, 2026 at 5:24 PM GMT+9 2 min read

In this article:

INCY

-1.21%

XBI

-0.55%

^GSPC

-0.00%

Headquartered in Wilmington, Delaware, Incyte Corporation (INCY) discovers, develops, and commercializes innovative therapies that confront some of medicine’s toughest challenges. Commanding a market cap of roughly $19.6 billion, the company targets blood cancers, solid tumors, immune-mediated disorders, and dermatological diseases.

Over the past 52 weeks, INCY stock has surged 49%, comfortably eclipsing the S&P 500 Index ($SPX) 14.4% gain during the same period. Year-to-date (YTD), INCY stock remains marginally positive, while the broader index has gained 1.4%.

More News from Barchart

Strategy Keeps Buying Bitcoin as Crypto, MSTR Stock Prices Plunge. How Should You Play It Here?

This Is the Top-Rated Dividend Stock to Buy in February 2026

Down 18% From Its Recent High, Should You Buy the Dip in Sandisk Stock?

Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today!

Against its sector yardstick, the State Street SPDR S&P Biotech ETF (XBI) has advanced 40% over the past year and risen 2.2% YTD, narrowly outperforming INCY stock in the shorter window.

www.barchart.com

However, on Feb. 10, the market greeted Incyte’s fourth-quarter 2025 results with a frown, sending shares down 8.2%. Ironically, the company delivered revenue growth that surpassed Wall Street expectations. The top line surged 27.8% year over year to $1.51 billion, comfortably exceeding analysts’ $1.35 billion estimate.

However, adjusted EPS reached $1.80, falling short of the $1.92 Wall Street forecast, though it increased 25.9% from the prior-year level. Management credited strong commercial execution across Jakafi and Opsalura and highlighted meaningful late-stage pipeline progress.

Looking ahead, they have anchored their outlook in anticipated launches in late 2026 and early 2027, sustained investment in pivotal trials, and potential regulatory approvals. For fiscal 2026, Incyte’s management projects total net product revenue between $4.77 billion and $4.94 billion.

Analysts, for their part, forecast fiscal 2026 diluted EPS of $6.66, implying 19.4% year over year growth. Importantly, Incyte has topped EPS estimates in three of the past four quarters, while missing in just one.

Wall Street sentiment remains firmly supportive, assigning INCY stock an overall “Moderate Buy” rating. Among 26 analysts, 12 issue a “Strong Buy,” 13 recommend “Hold,” and one assigns a “Strong Sell.”

www.barchart.com

Importantly, analyst sentiment has improved from three months ago, when 11 analysts carried a “Strong Buy” stance.

Story Continues  

Recent price-target revisions underscore the steady confidence. On Feb. 6, Piper Sandler’s Allison Bratzel reiterated her “Overweight” rating and lifted her price target to $110 from $102. That same day, Stifel’s Stephen Willey nudged his price target higher to $120 from $119 and maintained a firm “Buy” rating.

Moreover, HC Wainwright’s Mitchell S. Kapoor also reaffirmed a “Buy” rating on Feb. 5 and held the price target at $135.

Taken together, these targets provide a crisp sentiment snapshot. The average price target of $105.41 suggests 6.6% upside from current levels, while HC Wainwright & Co’s Street-high $135 target signals 36.6% gain from current levels.

_ On the date of publication, Aanchal Sugandh did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com _

Terms and Privacy Policy

Privacy Dashboard

More Info